Table 1.

Serology, clinical data and diagnosis confirmation of the ten ASD subjects with CD or positive CD serology

No.	Age (months)	Sex	tTG Ig A (U/ml)	EMA	AGA IgA (U/ml)	AGA IgG (U/ml)	Risk factor and clinical presentation	CD diagnosis
1	27	F	>200.0	+	15.0	127.0	Inappetence	MDB +
2	67	M	40.7	+	8.0	18.9	None	MDB +
3	41	M	35.0	+	9.3	41.0	CD in the sister	MDB +
4	44	M	102.0	+	1.4	1.1	None	MDB +
5	24	F	11.6	-	0.2	6.4	Diarrhea	MDB +
6	60	M	>200	+	93.0	85.5	None	HLA +
7	44	F	3.6	+/-	1.2	17.0	Growth failure	DH
8	20	M	23.0	+	1.4	9.0	None	n.p.
9	44	M	15.0	+	1.6	9.6	None	n.p.
10a	58	F	n.a.	n.a.	n.a.	n.a.	Growth failure Dental enamel defects	MDB +, HLA +

M male, F female, tTG Ig A anti-transglutaminase antibodies, EMA anti-endomysium antibodies, AGA IgA and IgG: anti-gliadin antibodies; cut -off values for tTG IgA, AGA IgA and AGA IgG: positive: > 10U/ml; borderline: 7–10 U/ml, negative: <7 U/ml; EMA: “+”: positive result; “-“: negative result; “+/-“: doubt result; n.p. not performed, n.a. not available, HLA+ human leukocyte antigen positivity, MDB + multiple duodenal biopsies positivitym, DH Duhring Dermatitis Herpetiformis

^aASD patient who had received a CD diagnosis before the hospitalization in our ASD Unit and for which serological data are not available